Last reviewed · How we verify
nicotine patch, experimental use
At a glance
| Generic name | nicotine patch, experimental use |
|---|---|
| Also known as | Nicoderm Clear 21 mg, Nicoderm Clear 14 mg, Nicoderm Clear 7 mg |
| Sponsor | University of Vermont |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients (NA)
- Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV (NA)
- Effect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Undergoing Thoracic Surgery: A Randomized Controlled Pilot Study (NA)
- Combination of Acupuncture, Auricular Acupressure and Nicotine Replacement Therapy for Smoking Cessation (NA)
- Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit) (PHASE2)
- Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (NA)
- C-FLASH (Cigarillo Flavor and Abuse Liability, Attention, and Substitution in youtH) (NA)
- Personalized Dosing of Nicotine Replacement (NRT to Effect) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nicotine patch, experimental use CI brief — competitive landscape report
- nicotine patch, experimental use updates RSS · CI watch RSS
- University of Vermont portfolio CI